Caribou, MaxCyte enter CRISPR license agreement

By The Science Advisory Board staff writers

May 7, 2020 -- Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

Under the agreement, Caribou gains rights to the use of MaxCyte's Flow Electroporation technology and ExPert platform for advancement of its CRISPR gene-edited allogenic T-cell therapy. Caribou will obtain nonexclusive clinical and commercial rights to the platform and in return MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to licensing fees.
Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.